PLOS: DNA Science

MARCH 28, 2024

FDA classifies it as a “nonsteroidal treatment” – not a gene therapy, but it affects gene expression. A gene-based treatment would have to alter many cells to exert a noticeable effect. In 2023, two gene-based treatments became available. Muscle makes up about 40 percent of body weight. million DNA bases.

FDA Approval 98

FDA Approval Treatment FDA DNA 98

The Pharma Data

DECEMBER 4, 2020

Alzheimer Disease Tied to Adverse Financial Events. 4, 2020 — Alzheimer disease and related dementias (ADRDs) are associated with adverse financial events years prior to clinical diagnosis, according to a study published online Nov. Professional. FRIDAY, Dec. 30 in JAMA Internal Medicine. Lauren Hersch Nicholas, Ph.D.,

Disease 52

Disease International Treatment Research 52

Broad Institute

NOVEMBER 6, 2024

For some patients, this treatment results in striking and long-lasting remission — but for a subset, it triggers complications ranging from mild rash to potentially deadly brain and heart inflammation. We know a bit more in terms of treatments to try, but they don’t always work.

Research 124

Research Immune Response Hospitals Therapies 124

ASPET

SEPTEMBER 22, 2023

These results suggest that brain damage can be long-lasting or permanent if nerve agent-induced SE in infant victims is treated with midazolam at a delayed timepoint after SE onset, while antiglutamatergic treatment with tezampanel and caramiphen provide significant neuroprotection.

Treatment 100

Treatment FDA Drugs 100

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. 1 Secondary endpoints included time to cytotoxic chemotherapy, time to pain progression, time to chronic opioid use, and time to skeletal-related events. [3] 10 months. [5]

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

Alta Sciences

AUGUST 28, 2023

Altasciences Completes Successful Phase I Trial of Ischemix’ Novel Compound for Treatment of Traumatic Brain Injury (TBI) pmjackson Mon, 08/28/2023 - 14:04 Laval, Québec, August 30, 2023 – Altasciences is pleased to have completed a Phase I trial on Ischemix, Inc.’s The trial was performed at Altasciences’ clinical facility in Montréal.

Trials 40

Trials Treatment Clinical Pharmacology Pharmacokinetics 40

The Pharma Data

MAY 13, 2021

Product Name: Treatment Plans That Worked. Click here to get Treatment Plans That Worked at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. Order 576 Treatment Plans That Worked here.

Treatment 52

Treatment Production Licensing Licensing 52

The Pharma Data

NOVEMBER 8, 2021

Bristol Myers Squibb moment blazoned the Phase 3 CheckMate-816 trial met the primary endpoint of bettered event-free survival (EFS) in cases with resectable stage IB to IIIAnon-small cell lung cancer (NSCLC). The primary endpoints of the trial are pathologic complete response (pCR) and event-free survival (EFS). About CheckMate-816.

Trials 52

Trials Clinical Trials Treatment Clinical Development 52

The Pharma Data

JUNE 30, 2021

With a median follow-up of two years, the study met the primary endpoint of event-free survival (EFS; hazard ratio 0.398, p <0.0001). Event-free survival is defined as time from randomization to disease progression, commencement of new lymphoma therapy, or death from any cause. This press release features multimedia.

Therapies 52

Therapies Treatment Virus Vaccine 52

The Pharma Data

MAY 16, 2022

Food and Drug Administration (FDA) has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP). There is no cure for HIV or AIDS. About Lenacapavir.

FDA 52

FDA Treatment Science Therapies 52

Drug Target Review

JULY 1, 2024

As a non-opioid, SRP-001 also eliminates abuse potential, positioning it as a safer and effective drug candidate for the treatment of acute and neuropathic pain and migraine headache. In Phase I clinical trials, SRP-001 showed no serious adverse events among 56 healthy volunteers, highlighting its safety.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

Broad Institute

NOVEMBER 6, 2024

Launched in 2017, this is a first-of-its-kind program in North America focused on improving the diagnosis, treatment, and understanding of serious immunotherapy complications, which can affect nearly every organ system.

Immune Response 118

Immune Response Medical Schools Clinical Trials Treatment 118

The Pharma Data

FEBRUARY 25, 2021

Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. There were no treatment emergent serious adverse events observed in any AGN-190584 treated participants. The most common treatment emergent non-serious adverse events occurring at a frequency of ?5%

Treatment 52

Treatment Drugs Production Disease 52

The Pharma Data

JANUARY 4, 2021

05, 2021 (GLOBE NEWSWIRE) — Polyphor AG (SIX: POLN) announced today that Gökhan Batur, Chief Executive Officer, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Thursday, January 7 from 8:00AM Eastern Standard Time. Investors can pre-register for the event here.

Clinical Development 52

Clinical Development Trials Treatment Research 52

The Pharma Data

NOVEMBER 25, 2020

AHA: Ablation Better Than Meds for Initial A-Fib Treatment. 25, 2020 — Cryoballoon ablation is superior to drug therapy as an initial treatment for the prevention of atrial arrhythmia recurrence in patients with paroxysmal atrial fibrillation , according to a study published online Nov. Professional. WEDNESDAY, Nov. Wazni, M.D.,

Treatment 52

Treatment Therapies Disease Drugs 52

The Pharma Data

FEBRUARY 25, 2022

If approved, rimegepant will be the first oral CGRP receptor antagonist in the EU, and the only migraine medication approved for both acute and preventive treatment. Pfizer is proud to have a strong footprint in Europe, which will help bring this important potential new treatment option to millions of adults in Europe living with migraine.”.

Treatment 52

Treatment Small Molecule FDA Approval Therapies 52

The Pharma Data

APRIL 16, 2021

for the treatment of COVID-19 – as planned with the FDA – follows the modification of contracts with the U.S. Lilly developed bamlanivimab and etesevimab for administration together to meet the potential challenge of treatment-resistant variants likely to resist treatment with either monoclonal antibody used alone.

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

JANUARY 4, 2021

Investors can pre-register for the event here. Eduardo Schiffrin, Medical Director, will participate in a panel discussion at the LifeSci Partners 10 th Annual Healthcare Corporate Access Event on Friday, January 8 from 11am Eastern Standard Time. Investors can pre-register for the event here. LAUSANNE, Switzerland, Jan.

Disease 40

Disease Therapies Treatment Production 40

The Pharma Data

MARCH 9, 2022

Treatment-emergent adverse events were comparable between PAXLOVID (23%) and placebo (24%), most of which were mild in intensity. million treatment courses delivered thus far and 30 million expected by July to help combat this devastating disease. Pfizer Inc.

Treatment 52

Treatment Pharmacokinetics Hospitals Trials 52

DrugBank

OCTOBER 17, 2024

Bayesian adaptive randomization , for example, can dynamically allocate patients to different treatment arms based on accumulating data, ensuring that more patients receive the most promising treatment. Machine learning algorithms can be trained on historical data to identify patterns and anomalies indicating potential safety concerns.

Drug Development 71

Drug Development Metabolic Stability Clinical Trials Drugs 71

The Pharma Data

NOVEMBER 17, 2021

The blessing of VUMERITY provides a new oral treatment option with low gastrointestinal termination rates that may help cases to start and cleave to treatment,” said Simon Faissner,M.D., In EVOLVE-MS-2, the rate of overall treatment termination was lower in actors treated with VUMERITY compared to those treated with TECFIDERA (1.6

Treatment 52

Treatment Marketing Clinical Trials Biosimilars 52

The Pharma Data

APRIL 6, 2021

Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD). “We remain confident in baricitinib and believe it has the potential to be an effective new treatment option for these patients.”

Treatment 52

Treatment Clinical Trials Therapies Drugs 52

The Pharma Data

DECEMBER 15, 2020

Less Invasive Treatment Feasible for Early-Stage Rectal Cancer. The researchers found no deaths within 30 days of initial treatment; one patient assigned to organ preservation died within six months following conversion to total mesorectal excision. Professional. TUESDAY, Dec. 10 in The Lancet Gastroenterology & Hepatology.

Treatment 52

Treatment Clinical Trials Pharmaceuticals Trials 52

The Pharma Data

MARCH 29, 2022

Application based on CheckMate -816, the only Phase 3 trial to demonstrate improved event-free survival and pathologic complete response with an immunotherapy-based combination in the neoadjuvant setting of NSCLC. Opdivo -based treatments have shown clinical benefit in four Phase 3 trials in earlier stages of cancer.

Treatment 52

Treatment Clinical Trials Trials Immune Response 52

SCIENMAG: Medicine & Health

JANUARY 16, 2024

Scaling drugs to a patient’s weight prevents adverse events from overtreatment and treatment failure due to underdosing. Knowing a patient’s weight is necessary for many weight-based medications such as thrombolytics, anticoagulants and numerous cardiovascular medications. Credit: Alex Dolce, Florida Atlantic University […]

Research 89

Research Treatment Drugs 89

The Pharma Data

OCTOBER 22, 2020

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. FOSTER CITY, Calif.–(BUSINESS –(BUSINESS WIRE)–Oct. 22, 2020– Gilead Sciences, Inc.

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

The Pharma Data

JULY 25, 2021

Allergan, an AbbVie company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. of patients discontinuing due to adverse events.

Treatment 52

Treatment Production Disease FDA 52

The Pharma Data

MARCH 26, 2021

Despite continuous innovations in the treatment landscape, unmet needs remain. Overall, the number of treatment-emergent adverse events reported was similar between the ponesimod and teriflunomide treated groups, and the majority were mild/moderate and did not warrant treatment discontinuation. vs. 10.4%).

Treatment 52

Treatment Pharmaceutical Companies Pharmaceuticals FDA Approval 52

The Pharma Data

AUGUST 30, 2021

Approval marks an important transformation in the treatment of more than 13 million people suffering from chronic kidney disease in Japan. 4 Forxiga is the first ever approved medicine for the treatment of the disease in Japan. Both Companies will co-promote for the treatment of CKD. In 2013, AstraZeneca K.K.

Treatment 52

Treatment Trials Disease Clinical Trials 52

The Pharma Data

APRIL 16, 2021

Opdivo in combination with Cabometyx was generally well tolerated, with a low rate of treatment-related discontinuations. The combination of Opdivo and Cabometyx was well tolerated, with safety reflective of the known profiles of both medicines and a low rate of treatment-related adverse events (TRAEs) leading to discontinuation.

Treatment 52

Treatment Trials Clinical Trials Immune Response 52

Covalent Modifiers

SEPTEMBER 19, 2023

No dose-limiting toxic effects or treatment-related deaths were reported. Treatment-related adverse events occurred in 127 patients (93%); grade 3 events occurred in 15 patients (11%) and a grade 4 event in 1 patient (1%). Among patients with NSCLC, a confirmed response was observed in 53.4% months (95% CI, 8.8

Pharmacokinetics 59

Pharmacokinetics DNA Treatment 59

The Pharma Data

MARCH 18, 2022

Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab 1. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.1 months (95% CI: 3.4

Treatment 52

Treatment Trials FDA Approval Disease 52

The Pharma Data

APRIL 26, 2022

This approval follows the recent sNDA approval for Veklury for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19. For hospitalized pediatric patients who do not require invasive mechanical ventilation and/or ECMO, a 5-day treatment course is recommended.

Treatment 52

Treatment Hospitals Science Licensing 52

The Pharma Data

AUGUST 22, 2021

The findings, published online in The American Journal of Geriatric Psychiatry , evaluated the long-term use of AUSTEDO with the total motor Abnormal Involuntary Movements Scale (AIMS) score, and measures of treatment success and quality of life. About AUSTEDO (deutetrabenazine) Tablets. Indications and Usage. IMPORTANT SAFETY INFORMATION.

Treatment 52

Treatment Disease Therapies Pharmaceuticals 52

The Pharma Data

FEBRUARY 24, 2022

Today’s approval will provide a treatment option for a wider range of patients with heart failure,” said Norman Stockbridge, M.D., Despite therapies in multiple drug classes, mortality remains high and treatment options for a broader range of patients are needed.

FDA Approval 52

FDA Approval FDA Treatment Hospitals 52

The Pharma Data

NOVEMBER 27, 2020

FDA Approves Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma. the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. NEW YORK, Nov.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

The Pharma Data

MAY 27, 2022

The FDA’s decision is informed by the results of Pfizer’s nonclinical studies and a Phase 2a clinical study of ervogastat/clesacostat, which showed that treatment with ervogastat/clesacostat reduced liver fat with a favorable safety and tolerability profile. Pfizer Inc. NYSE: PFE) today announced the U.S.

Treatment 52

Treatment FDA Therapies Vaccine 52